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Abstract
Objective: To examine the diversity in paediatric vision and hearing screening programmes in Europe.
Methods: Themes for comparison of screening programmes derived from literature were used to compile three question-
naires on vision, hearing, and public health screening. Tests used, professions involved, age, and frequency of testing seem to
influence sensitivity, specificity, and costs most. Questionnaires were sent to ophthalmologists, orthoptists, otolaryngologists,
and audiologists involved in paediatric screening in all EU full-member, candidate, and associate states. Answers were cross-
checked.
Results: Thirty-nine countries participated; 35 have a vision screening programme, 33 a nation-wide neonatal hearing screening
programme. Visual acuity (VA) is measured in 35 countries, in 71% of these more than once. First measurement of VA varies
from three to seven years of age, but is usually before age five. At age three and four, picture charts, including Lea Hyvarinen, are
used most; in children over four, Tumbling-E and Snellen. As first hearing screening test, otoacoustic emission is used most in
healthy neonates, and auditory brainstem response in premature newborns. The majority of hearing testing programmes are
staged; children are referred after 1–4 abnormal tests. Vision screening is performed mostly by paediatricians, ophthalmologists,
or nurses. Funding is mostly by health insurance or state. Coverage was reported as >95% in half of countries, but reporting was
often not first-hand.
Conclusion: Largest differences were found in VA charts used (12), professions involved in vision screening (10), number of
hearing screening tests before referral (1–4), and funding sources (8).
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Introduction
Childhood sensory functions play a key role in intellectual
and social development. Vision or hearing impairment
aﬀects both personal and societal health of children.
Earlier detection of visual or hearing deﬁcits improve out-
come.1–4 Vision and hearing screening programmes are
based on the same general principles, but vary both
within and across European Union (EU) countries,
regarding tests used, age of testing, frequency of testing,
professions involved in screening, referral procedure,
funding, and coverage. Such diﬀerences can result in
health inequities. No screening, or screening with little
population coverage, can result in delayed provision of
the correct treatment and increased disease burden.
Excessive screening can result in inappropriate interven-
tions and increased costs for health care systems.
Vision screening and subsequent treatment has reduced
the occurrence of insuﬃciently detected and treated
amblyopia.5 In the Netherlands, amblyopia is now
detected more than two years earlier than in the 1970s.6
Early screening and detection of hearing disorders, and
timely intervention (eg. cochlear implantation or hearing
aid) largely prevents delayed language development,1,2,7
and also improves general developmental outcome at
age 3–5.3
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Despite increased consciousness that vision and hearing
screening is eﬀective, diﬀerences exist in implementation
between countries. A 2002 survey of vision screening pro-
grammes in 190 countries found that screening was often
state funded, visual acuity (VA) was always tested, and that
in the EU screening was predominantly voluntary.8 In a
2012 survey of the International Orthoptic Association,
98% of responders indicated that vision screening pro-
grammes existed in their country, (44% were national pro-
grammes). Screening was performed by a wide range of
professionals.9 An overview of universal newborn hearing
screening (UNHS) in 24 European countries from
2004-2006 showed that in several countries UNHS pro-
grammes reached more than 95% of all neonates, but in
many other countries programmes were recently intro-
duced or were only partially functioning.10 Other reports
on national neonatal hearing screening programmes raise
issues on implementation, test procedures, type of tests,
coverage, detected cases of hearing loss, and costs.11–19
A Health Technology Assessment review in 200820
re-examining the cost-eﬀectiveness of vision screening up
to age 4-5 (following previous report in 199721) found
that, based on the accepted value of a Quality-adjusted
life year, the cost-eﬀectiveness of screening for amblyopia
depends on the long-term utility eﬀects of unilateral vision
loss and that there was currently no sustainable evidence
of utility loss that would render any form of screening
likely to be cost-eﬀective.20 Keren et al. concluded that
UNHS in general has the potential for long-term cost
savings compared with selective hearing screening and
no screening.22 Burke et al found that the cost-eﬀective-
ness of hearing screening depended mainly on the cost of
the screening intervention per patient and on the preva-
lence of hearing loss in the population.23
We aimed to compile an inventory of population-based
vision and hearing screening programmes for children in
Europe, and to quantify and examine the diﬀerences. This
study should assist those countries without a screening
programme and new EU member states in selecting
which screening protocol to adopt. If large diﬀerences
between programmes in EU countries are found, further
study on the relative costs and eﬀectiveness of the diﬀerent
approaches to screening will be necessary.
Methods
Drawing particularly from ﬁve major cost-eﬀectiveness
analyses,20,21,23–25 we selected the following items to
formulate vision (Q1) and hearing (Q2) screening
questionnaires:
. Type of tests, eg. visual acuity chart or hearing screen-
ing device used (otoacoustic emission [OAE], auto-
mated auditory brainstem response [aABR])
. Professions involved in screening, eg. nurses, orthop-
tists, doctors
. Funding, eg. State, health insurance
. Coverage, percentage of screened children.
Questions formulated in a focus group were structured as
multiple-choice with room for comments and multiple
answers (See Appendix, Q1, Q2). All forms of screening
for vision or hearing problems were included (eg. inspec-
tion of the eyes was also counted as form of vision screen-
ing). To obtain a broader perspective of screening systems,
a short public health questionnaire (Appendix Q3) to pro-
vide background information on screening and screening
systems in all countries was developed through extrapola-
tion of the vision and hearing questionnaires.
In each of the 28 EU full member states, ﬁve candidate
states, potential candidate state Albania and associated
states Israel, Moldova, Norway, and Switzerland, a paedi-
atric ophthalmologist, orthoptist, otolaryngologist, audi-
ologist, and screening professional were selected, based on
their involvement in paediatric vision and hearing screen-
ing, and asked to complete the questionnaires for their
own country. Public health representatives were identiﬁed
through the Ministries of health or recommendation from
the vision and hearing representatives.
The questionnaire included questions about screening
tests, age, and frequency of screening. Diﬀerent tests can
be used to screen for one disorder, but screening pro-
grammes can also focus on more than one disorder.
Two-stage or multiple-stage testing improves screening
speciﬁcity but increases screening costs, although higher
speciﬁcity can reduce diagnostic follow up costs.23,26
Questions about the range of professions involved in
screening were included because this inﬂuences the quality
and costs of screening. Screening tests with higher sensi-
tivity and speciﬁcity might require more highly educated
personnel and higher salary costs, which will increase the
costs of screening. This increase in costs should be
balanced with the increase in sensitivity and speciﬁcity.
Box 1. Glossary.
aABR: automated Auditory Brainstem Response; detects responses
in the brainstem after offering clicks of 35 or 40 dB via headphones.
Amblyopia (lazy eye): reduced vision, usually in one eye caused
by abnormal visual experience in early childhood e.g. strabismus and
refractive error.
Bru¨ckner test: A direct ophthalmoscope is used in a darkened
room and the red reflex in both eyes is assessed simultaneously at
0.6 to 0.9 metres. The colour and brightness of the red reflexes are
compared. The colour is often more orange than red. The test is
easy and quick to perform and can reliably detect media opacities.
Strabismus and refractive error can also be detected, but with a
lower sensitivity. Refractive error can give a yellow-white edge to
a red reflex.
Hirschberg test: corneal light reflex test. The corneal light reflex
test is performed to assess ocular alignment. The test is performed
by shining a light into the child eyes from a distance and observing
the reflections on the cornea with respect to the pupil. The location
of the light reflexes should be symmetric.
OAE: Otoacoustic emissions; sounds produced by inner ear hair
cells if the hearing threshold is better than 35 dB and picked up by a
microphone in the ear canal.
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The questionnaire also covered funding sources, including
state, regional, municipal, Health insurance, parental
and/or charity. The choice of funding agencies will inﬂu-
ence the equity of screening, competitiveness, costs, cover-
age, and cost-eﬀectiveness. Questions about coverage were
included because the participation frequency of a screen-
ing programme is crucial for its eﬀectiveness, and to make
screening worthwhile from a population perspective. Low
coverage can lead to delayed provision of the correct
treatment and increased disease burden. If screening is
free or compulsory, coverage will be higher. Acceptable
participation frequencies may be reached by incorporating
screening into an existing system with a high participation
rate, eg. vaccination programmes or school start.
Questionnaires were emailed from December 2013 until
April 2014. Clinicians involved in population-based
screening were identiﬁed and their answers were cross-
checked with those given by general screening profes-
sionals. If answers were ambiguous the questionnaires
were returned to both the clinician and the screening pro-
fessional and they were asked to contact each other to
agree corrections. Overviews of the questionnaire answers
were circulated three times to all representatives. All rep-
resentatives were asked to review and correct any errors in
the overviews for their own and neighbouring countries.
The overviews were also checked by external experts,
involved ﬁrst-hand in vision and hearing screening.
Results
In all 39 countries (including two separate regions,
Flanders and Wallonia, in Belgium), representatives
were found. Vision representatives were found in 36 coun-
tries, hearing representatives in 38, and public health rep-
resentatives in 23 (Table 1).
Vision
Information on vision screening programmes was
obtained from 36 countries including two Belgian regions.
No information could be obtained from Albania,
Macedonia, and Moldova. Thirty-ﬁve countries have a
vision screening programme in place. In Belgium,
Bulgaria, Estonia, France, Romania, Spain, and
Switzerland this is a regional programme. In several coun-
tries with a national vision screening programme in place,
regional diﬀerences in screening protocols exist.
Infant and preverbal screening tests. Infant screening (age 0–4
months) included inspection, ﬁxation, red reﬂex testing,
Hirschberg test, Bru¨ckner test, Cover test, pupillary
reﬂexes, and motility. Most countries perform a combin-
ation of two or more of these tests. In Bulgaria, Greece,
and Poland no infant screening is performed. In Germany
only eye inspection is performed. In Ireland, Montenegro,
and Spain, eye inspection is combined with red reﬂex test-
ing. In Cyprus, Italy, Lithuania, and Malta only red reﬂex
testing is done. In Latvia this is combined with motility
testing. Preverbal screening (age 6-30 months) includes the
same tests. Preverbal screening is not performed in eight
countries, but most countries combine two or more tests.
Visual acuity (VA) measurements. In all countries VA is
tested, but the age of the ﬁrst measurement varies from
3–7 years. In a third of countries VA is tested once, one
third twice, and in one third more than twice. In most
countries, VA measurements are repeated at an older
Table 1. Eligible countries.
Country EU status Vision Hearing Public
Albania P.C.  þ þ
Austria M. þ þ 
Belgium Flanders M. þ þ þ
Belgium Wallonia M. þ þ 
Bulgaria M. þ þ þ
Croatia M. þ þ þ
Cyprus M. þ þ 
Czech Republic M. þ þ þ
Denmark M. þ þ 
Estonia M. þ þ 
Finland M. þ þ þ
France M. þ þ þ
Germany M. þ þ þ
Greece M. þ þ þ
Hungary M. þ þ þ
Iceland C. þ þ þ
Ireland M. þ þ 
Israel A. þ þ þ
Italy M. þ þ 
Latvia M. þ þ 
Lithuania M. þ þ 
Luxembourg M. þ þ 
Macedonia C.   þ
Malta M. þ þ þ
Moldova A.  þ 
Montenegro C. þ þ þ
Netherlands M. þ þ þ
Norway A. þ þ 
Poland M. þ þ 
Portugal M. þ þ þ
Romania M. þ þ 
Serbia C. þ þ þ
Slovakia M. þ þ 
Slovenia M. þ þ þ
Spain M. þ þ þ
Sweden M. þ þ þ
Switzerland A. þ þ 
Turkey C. þ þ þ
United Kingdom M. þ þ þ
(EU status: A¼ associated state, C¼Candidate, M¼ full member,
P.C.¼ potential candidate).
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age. In children aged 4 and younger VA charts are most
commonly picture charts and the Lea Hyvarinen chart,
above age 4, Tumbling-E and Snellen are most often used.
Personnel and referral. Screening is mostly performed by
paediatricians, ophthalmologists, and/or nurses. In most
countries children are referred to ophthalmologists for
further examination; in Latvia they are referred to the
General Practitioner (GP), in the UK they may also be
referred to joint orthoptic and optometry clinics or
optometrists, in Malta to either the orthoptist or optom-
etrist, and in the Netherlands they are mostly referred via
the GP to an orthoptist or ophthalmologist, but some-
times directly to an orthoptist, ophthalmologist, optom-
etrist, or optician.
Funding. In most countries vision screening is free, except
for the Czech Republic, Switzerland, and Turkey.
Funding is 33% (partially) provided by Health
Insurance and 53% (partially) by the State. Parents and
charity pay (part of the) screening in the Czech Republic,
Latvia, Romania, Slovakia, Spain and Turkey.
Coverage. Coverage varied from just starting (Estonia,
Portugal, Turkey) to more than 95% in Austria, Czech
Republic, Denmark, Finland, Flanders, Germany,
Hungary, Iceland, Luxembourg, the Netherlands,
Norway, Serbia, Slovenia, Sweden, and parts of the UK.
Coverage of diﬀerent testing time points varied, as did
number of children screened, dependent on the age at
which testingwas performed. The highest coverage percent-
age was regarded as coverage for each particular country.
Further detailed data is presented in table 2 and
Appendix Map 1.
Hearing
Information on neonatal hearing screening programmes
was obtained from 38 countries (including two Belgian
regions). No information could be obtained from
Macedonia. Nationwide UNHS programmes exist in 33
of 38 countries. Malta has nationwide selective screening
only for infants from neonatal and paediatric IC units. In
Bulgaria, Moldova, and Serbia local selective screening
programmes for high risk groups (premature newborns)
exist. In Albania a pilot nationwide UNHS programme
was discontinued due to lack of funds.
Tests. The most widely used audiometric test is OAE.
Flanders has used aABR in all neonates, but in 2013 intro-
duced additional auditory steady state responses (ASSR).
Some regions in Denmark, Estonia, France, Germany,
Spain, and Sweden use aABR, OAE, or both in the
same infant as ﬁrst test in healthy babies. In nearly all
programmes both ears are tested, except in Finland and
Switzerland, where one or two ears are tested, depending
on the institution or the presence of risk factors. Testing is
not staged in ﬁve countries, two-staged in 13 countries,
three-staged in 19 countries, and 4-staged in one country.
aABR is used as ﬁnal stage in the majority of countries.
In high risk groups, eg. premature newborns, most pro-
grammes use aABR or a combination of OAE and aABR,
but in eight countries OAE only is used. In Wallonia
(Belgium) all premature infants undergo full ABR. In
less than half of the countries, a hearing test in pre-
school or early school age children is a regular part of
health screening programmes.
Referral. Neonates who do not pass the test are referred to
a combined audiology/ ear, nose, throat (ENT) institution
in most countries, in some countries to an audiologist, and
in a few countries to an ENT specialist.
Funding. In most countries the government or health insur-
ance ﬁnances the neonatal hearing screening programme.
Other reported funding includes hospital, parents, and
private funds.
Coverage. UNHS programmes cover an estimated 10–50%
in Romania, 50–95% in nine countries, and more than
95% in 23 other countries. Malta has a nationwide select-
ive screening programme with good coverage, whereas
Bulgaria, Moldova, and Serbia have local selective screen-
ing programmes, with low coverage. Albania’s discontin-
ued pilot nationwide UNHS programme had a low
coverage. Further detail is available in table 3 and
Appendix Map 2.
Public health
Extra information on public health screening programmes
was obtained from 23 countries including one Belgian
region (Flanders). All have a public health screening pro-
gramme, but in Albania, Belgium, and Spain this is a
regional programme. In the Netherlands and Sweden a
combination of national and regional programmes
exists. Almost all countries have a programme for all chil-
dren, except Albania, where screening is selective.
Screening is not free in Albania, Bulgaria, and Czech
Republic, and is compulsory in Bulgaria, Flanders,
Greece, Hungary, and Turkey.
Tests. Weight, height and head circumference are measured
in all countries, cardiac function in all but Albania, lung
function in all but Albania and Flanders, vision in all but
Albania and Turkey, hearing in all but Albania andMalta,
motor skills in all but Czech Republic and the UK, speech
and language development in all but Albania, Bulgaria,
Czech Republic, and the UK, cognitive development in
all but Albania, Czech Republic, Flanders, and the UK.
Psychosocial development is assessed in all countries but
Albania, Bulgaria, Czech Republic, Flanders, Germany,
Israel, Sweden, and the UK.
Referral, funding and coverage. Referral is most often to a
specialist. Funding is provided mostly by the government
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Table 2. Vision screening programmes in 36 European countries.
Country Scope Personnel 0–4mo 6–30mo Pres. Chart and age Auto. Also Funding Cov. (%)
Austria nat Ophth, ped, school þ þ þ Lea 3; 4; 5; 6  stereo insur, state >95
Belgium (Fl) YHC, nurse þ þ þ Pict 31/2, HOTV 41/2 þ both region >95
Belgium (W) nat Orth, ped, other þ þ þ Snel 31/2; 6 þ  region >40
Bulgaria loc GP  þ  Pict, E 7  colour insur
Croatia nat Ophth, ped, school þ þ þ Pict, Lea 4, E 6; 61/2   insur, state >90
Cyprus nat School þ   Snel 61/2; 7   state >80
Czech rep nat Ophth, orth,
ped, YHC,
optom, other
þ þ þ Pict; Lea 3, E 5,
Snel 7; 9; 11; 13; 15
Loc. colour insur, par region >95
Denmark nat Nurse, school, GP þ þ þ Pict 3; 4; 5; 6   region >95
Estonia loc Ophth, ped þ þ þ Lea 3, Lea; Snellen 6   insur start
Finland nat Nurse, school, GP þ þ þ Lea 3; 4; 51/2   state, munic >95
France loc Orth, ped,
nurse, school
þ þ þ Pict 4   insur, region >80
Germany nat Ped þ þ þ Lea; HOTV 3   insur >95
Greece nat Ophth   þ Snel 51/2  both state >60
Hungary nat Ped, nurse, school þ þ þ Pict 6 Loc. both insur, state >95
Iceland nat Ped, nurse þ þ þ Lea; HOTV 4,
HOTV; Snel 6
 stereo state >95
Ireland nat School þ þ  Snel 51/2   state >80
Israel nat Ped, nurse þ þ þ Pict 3; 6   state >80
Italy nat Ped þ  þ Snel (3); 6   region >80
Latvia nat Ophth, ped þ þ þ Cardiff 1, Pict; E 3,
E; numbers 61/2
 stereo state, par >60
Lithuania nat Ophth, ped þ þ þ Pict; E; Snel 6; 61/2; 7 þ  state
Luxembourg nat Orth, ped, nurse þ þ þ Pict; E 31/2, 41/2, 51/2, 61/2 þ both insur, state >95
Malta nat Orth, nurse,
optom, school
þ þ  Snel 3, Sher 51/2  stereo state >80
Montenegro nat Ped, nurse þ þ þ Snel 51/2   state
Netherlands nat YHC, nurse þ þ þ Pict 3, Lea; C 4   munic >95
Norway nat Nurse, GP, school þ þ þ Lea 4, Sher 6   munic >95
Poland nat Ped, GP  þ þ Pict 4, Snel 6   state >80
Portugal nat GP þ  þ Sher 4, E 5; E; C 51/2; 6   state start
Romania loc Ophth þ  þ Pict 3, Snel 4; 5 Loc.  state, charity >80
Serbia nat Ophth, ped þ þ þ Snel 61/2  both state >95
Slovakia nat Ophth, orth, ped þ þ þ Pict 3, Lea; E; C; Snel, 5; 6  both par, insur >90
Slovenia nat Ped, school þ þ þ Pict 3; 5 Snel 6; 7   insur >95
Spain loc Ped, ophth, optom þ  þ Pict 4, Snel 41/2; 5  stereo par, state
Sweden nat Nurse þ   HOTV 4, KM 6   region >95
Switzerland loc Ophth, orth, ped,
nurse, optic,
school, GP
þ þ þ Pict 4, Lea; E 41/2; 5, 51/2  stereo insur >80
Turkey start Ophth þ þ  E 5   par start
UK nat Orth, nurse, assist þ   Sonksen; Keeler 4; 5   region >95
Scope¼ scope of vision screening programme (nat¼ nation-wide, loc¼ local), Personnel: (ophth¼ ophthalmologist, ped¼ paediatrician, school¼ school physician,
YHC¼ youth health care physician, orth¼ orthoptist, optom¼ optometrist, GP¼ general practitioner, optic¼ optician, assist¼ practice assistant), Pres.¼ preschool
screening(screening before school age, school age varies across countries), Chart and age¼ visual acuity chart and age of testing (Pict¼ Picture chart, Lea¼ Lea
Hyvarinen Chart (picture) C¼ Landolt C, E¼ Tumbling E, KM¼ Konstantin Moutakis, Sher¼ Sheridan Gardiner, Snel¼ Snellen), Auto.¼ autorefraction/photorefraction,
Also¼ testing of stereopsis and/or colour vision, Funding¼ (Insur¼ health insurance, Munic¼Municipalities, Par¼ parents), Cov.¼ Coverage.
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or health insurance. Coverage is above 80% in all coun-
tries, except Albania. Further data is presented in table 4
and Appendix Map 3.
Questionnaire answer check
Changes were made based on the ﬁrst round of question-
naire answers. In hearing screening data: for Belgium
(Flanders) the ASSR was added as test for neonates at
risk; for Finland ‘‘testing one ear’’ was changed to ‘‘testing
one ear or both ears’’; for France ‘‘testing one ear and
testing both ears’’ was changed to ‘‘always testing both
ears’’; for Italy coverage of ‘‘>95%’’ was changed to
‘‘70%’’; Malta selective screening, not population-wide
screening, was conﬁrmed; for Poland ‘‘non-staged screen-
ing’’ was changed to ‘‘staged screening’’; for Israel, Italy,
Table 3. Overview of neonatal hearing screening programmes in 38 European countries.
Country Scope Strat Test St Last test Ears Test risk group Refer Funding Cov (%) Child
Albania past all OAE 3 full ABR 2 OAE ENT private <10 
Austria nat all OAE 3 aABR 2 OAE audio state >95 
Belgium (Fl) nat all aABRþ ASSR 2 aABR 2 aABRþASSR audio state >95
Belgium (W) nat all OAE 2 full ABR 2 full ABR both par, state 90 
Bulgaria loc select OAE 2 aABR 2 aABR both private, hosp 25
Croatia nat all OAE 3 aABR 2 aABR both insur >95 
Cyprus nat all OAE 3 aABR 2 aABR audio NGO >95 þ
Czech rep nat all OAE 1 2 OAE ENT insur >50
Denmark nat all OAE or aABR 2 aABR 2 OAEþaABR audio state >95 þ
Estonia nat all OAE or aABR 3 aABR 2 OAE both insur >95 þ
Finland nat all OAE 2 OAE 1/2 aABR both state >95 þ
France nat all OAE or aABR 3 aABR or full ABR 2 aABR both state >50 þ
Germany nat all OAE or aABR 2 aABR 2 aABR both insur >95 þ
Greece nat all OAE 1 2 aABR both par >50 þ
Hungary nat all OAE 2 OAE 2 aABR both insur, state >50 þ
Iceland nat all OAE 3 aABR 2 OAE both state >50 
Ireland nat all OAE 2 aABR 2 OAEþaABR audio state >95 
Israel nat all OAE 3 aABR 2 OAEþaABR audio state >95 þ
Italy nat all OAE 3 aABR 2 OAEþaABR both hosp 70
Latvia nat all OAE 3 ABR 2 aABR and/or other both state >95 þ
Lithuania nat all OAE 3 aABR 2 OAEþaABR both insur 50–90 
Luxembourg nat all OAE 2 OAE 2 aABR ENT state >95 þ
Malta nat select OAE 1 2 aABR both state >95
Moldova loc select OAE 2 aABR 2 OAE both int. project >50 
Montenegro nat all OAE 4 aABR 2 aABR both state >95 
Netherlands nat all OAE 3 aABR 2 aABR audio state >95 þ
Norway nat all OAE 3 aABR or full ABR 2 aABR both state >95
Poland nat all OAE 2 OAE 2 OAE both insur >95 
Portugal nat all OAE 3 aABR 2 aABR both hosp >95 
Romania nat all OAE 2 aABR 2 OAEþaABR both state >10 
Serbia loc select OAE 1 2 OAE both hosp 25 þ
Slovenia nat all OAE 3 aABR 2 aABR both insur >95 
Slovakia nat all OAE 2 OAE 2 aABR both insur, state >95
Spain nat all OAE or OAEþaABR 3 aABR 2 aABR or OAEþaABR audio state >95 
Sweden nat all OAE or aABR 3 aABR or full ABR 2 OAEþaABR or aABR both state >95 þ
Switzerland nat all OAE 1 1/2 OAE or aABR both hosp >95 þ
Turkey nat all OAE 3 aABR 2 aABR both state 90
UK nat all OAE 3 aABR 2 aABR audio state >95 þ
Scope¼ scope of hearing screening programme (nat¼ nation-wide, loc¼ local, past¼ pilot from 2004-2008), Strat¼ screening strategy (all¼ all neonates, select¼ only
neonates at risk e.g. prematures), Test¼ test used for well babies in the programme (first test when staged)( test a or test b¼ both tests are used in the programme, test
aþ test b¼ both tests are used in one neonate), St¼ stages (number of tests before referral), last test¼ test before referral if staged, ears¼ ears tested (both or only the
first ear with a pass), test risk group¼ test used in neonates at risk (first test when staged), refer¼ referred to ENT, audiological institution or a combination (both),
funding¼ (insur¼ health insurance, hosp¼ hospital, par¼ parents, NGO¼ non-government organization, int. project¼ international project), Cov¼ coverage (infants
screened/infants meant to be screened  100), child: standard hearing test in screening programme at child age.
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Lithuania, and Switzerland ‘‘only aABR testing’’ for neo-
nates at risk was corrected to ‘‘OAE and/or aABR’’.
Vision screening data was revised: for Austria funding
was changed from ‘‘health insurance’’ to ‘‘health insur-
ance and state’’, for Belgium (Flanders) personnel was
changed from ‘‘nurse’’ to ‘‘nurse and youth health care
physician’’, testing of stereopsis and colour vision was
added and VA chart was changed from ‘‘Landolt C’’ to
‘‘Pictures and HOTV’’; for Croatia VA chart was changed
from ‘‘only Tumbling-E’’ to ‘‘Pictures, Lea and Tumbling-
E’’; for Czech Republic Pictures and Lea chart were
added; for Denmark the ‘‘Snellen chart’’ was changed to
‘‘Pictures’’ and coverage was changed from ‘‘>80%’’ to
‘‘>95%’’; for Iceland Snellen chart was added; for Israel
coverage was changed from ‘‘>95%’’ to ‘‘>80%’’; for
Italy funding was changed from ‘‘state’’ to ‘‘regions’’;
for Latvia ‘‘Picture chart and Tumbling-E’’ was corrected
to ‘‘Cardiﬀ, Pictures, Tumbling-E and numbers’’;
for Norway the Sheridan Gardiner chart was added; for
Slovenia autorefraction was corrected as in Slovenia auto-
refraction is only performed in ophthalmology clinics for
referred children and not for screening; for Sweden the
Konstantin Moutakis chart was added; for the UK fund-
ing was corrected from ‘‘state’’ to ‘‘regions’’, and person-
nel were changed from ‘‘orthoptist, optician and
optometrist’’ to ‘‘orthoptist, nurse and practice assistant’’.
Discussion
This study showed that large diﬀerences exist in tests used,
age, and frequency of testing in paediatric population-
based vision and hearing screening programmes through-
out the EU. First measurement of VA varies from ages
3–7, but in most countries it is measured before age 5. In
children aged 3–4, picture charts, including Lea
Hyvarinen, are used most; in children over 4 Tumbling-
E and Snellen. Vision screening is performed mostly by
paediatricians, ophthalmologists, or nurses. As a ﬁrst
hearing screening test, OAE is used most in healthy neo-
nates, and ABR in premature newborns. The majority of
hearing testing programmes are staged. Children are
referred after one, two, three, or four abnormal tests.
Funding is by health insurance, state, regions, municipa-
lities, charity, hospital, parents, or private funding. A high
coverage is reached in most countries for both vision and
hearing screening.
Our study was limited by the diﬃculty in obtaining
referenced or ﬁrst-hand data sources from respondents.
Where possible we tried to maintain the quality of our
data by involving clinicians involved in population
based screening, and cross-checking their answers with
those from general screening professionals. Obtaining
accurate information on funding and coverage was the
Table 4. Public health screening programmes in 23 European countries.
Country Scope All Vision Hearing WHH Heart Lung Motor Speech Cog Psycho Funding Cov (%)
Albania loc    þ   þ    state, par >10
Belgium (Fl) nat þ þ þ þ þ  þ þ   state >95
Bulgaria nat þ þ þ þ þ þ þ  þ  state, insur >95
Croatia nat þ þ þ þ þ þ þ þ þ þ insur >95
Czech rep nat þ þ þ þ þ þ     insur >80
Finland nat þ þ þ þ þ þ þ þ þ þ state, munic >95
France nat þ þ þ þ þ þ þ þ þ þ state >95
Germany nat þ þ þ þ þ þ þ þ þ  insur >80
Greece nat þ þ þ þ þ þ þ þ þ þ state, par
Hungary nat þ þ þ þ þ þ þ þ þ state >95
Iceland nat þ þ þ þ þ þ þ þ þ þ state >95
Israel nat þ þ þ þ þ þ þ þ þ  state >95
Macedonia nat þ þ þ þ þ þ þ þ þ þ state, insur >95
Malta nat þ þ  þ þ þ þ þ þ þ state >95
Montenegro nat þ þ þ þ þ þ þ þ þ þ insur >95
Netherlands nat þ þ þ þ þ þ þ þ þ þ state, munic >95
Portugal nat þ þ þ þ þ þ þ þ þ þ state >95
Serbia nat þ þ þ þ þ þ þ þ þ þ insur >80
Slovenia nat þ þ þ þ þ þ þ þ þ þ insur >95
Spain loc þ þ þ þ þ þ þ þ þ þ state >95
Sweden nat þ þ þ þ þ þ þ þ þ  >95
Turkey nat þ  þ þ þ þ þ þ þ þ state >95
UK nat þ þ þ þ þ þ     state
Scope¼ public health screening programme (nat¼ nation-wide, loc¼ local), All¼ screening programme for all children, WHH¼weight, height and head circumference,
Cog¼ cognitive development, Psycho¼ psychosocial aspects, Funding (insur¼Health Insurance, par¼ parents, munic¼Municipalities) Cov¼ Coverage)
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most diﬃcult. Information on tests, personnel, and age
was easier to acquire. Coverage may have been overesti-
mated by the country representatives.
Screening for vision and hearing deﬁcits has similarities,
but also diﬀerences. An essential diﬀerence is that objective
tests are available for hearing screening at a very early age,
enabling screening directly after birth. This is probably the
reason for the more uniform approach and higher coverage
reported for hearing screening compared with vision
screening. We assumed that the personnel operating the
screening apparatus at the hospital or during home visits
would be a technician, so did not ask the profession expli-
citly. The only two tests for hearing screening are OAE and
aABR, so the major diﬀerence in hearing screening is the
number of stages before referral.Multiple stage screening is
more expensive, but yields higher speciﬁcity, which reduces
the number of false referrals to specialized and expensive
audiological care centres.23,26 There are most frequently
two or three stages of screening before referral, generally
with OAE as the ﬁrst test and aABR as last test. It has been
suggested that three stages may be more cost-eﬀective26,
but this is not based on combined use of OAE and
aABR. Pre-school or early school-age hearing tests may
potentially discover hearing loss acquired during the
years after birth, but this occurs rarely and these tests
have been abolished in many European countries.
The wide diﬀerences between European screening pro-
grammes may have occurred because these programmes
arose piecemeal, before robust evidence on eﬀectiveness
and cost-eﬀectiveness was available to guide protocol
design or implementation. In addition, most preventive
health care programmes are government funded and,
therefore, competition is lower than in curative health-
care. Further assessment is needed on the inﬂuence of
funding source (eg. state, health insurance, or municipa-
lities) on the eﬃciency of screening.
Further study should also be undertaken into the rela-
tive costs and eﬀectiveness of diﬀerent approaches to
screening, as in Europe, 12 diﬀerent VA charts are used,
10 professions are involved in vision screening, one to four
hearing screening tests take place before referral, and eight
funding sources are involved. The large number of screen-
ing tests used in vision screening should be compared.
Eﬃciency of screening (ie. sensitivity and speciﬁcity per
euro) should be calculated for screening performed by dif-
ferent screening professions.
We now plan to include data sources in a much larger
and more detailed questionnaire. The EUSEREEN study
group, an EU-wide consortium (see list at end of paper), is
currently preparing a Europe-wide study to compare and
optimize the cost-eﬀectiveness of vision and hearing
screening, and give country-speciﬁc advice in all candi-
date, associate, and full EU-member states.
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